Can any of the new obesity medications in development stand out from the pack? Which company just broke records with its IPO? And will the Food and Drug Administration allow greater access to experimental peptides? We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast.[2:37 PM]Undark’s Sara Talpos joins the podcast to discuss her reporting on the peptide BPC-157, and how its jumped from a Croatian lab to bodybuilding forums on Reddit to the FDA. (STAT co-published Talpos articles; the second piece was was supported by the Pulitzer Center). We also discuss the latest news in the life sciences, including obesity data from the American Diabetes Association meeting and a record-breaking IPO.
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from The Readout Loud
411: Capricor's data clash and a fugitive in the C-suite
410: A father’s mission to save his daughter, and allegations on telehealth GLP-1 prescribing
409: Predicting biotech clinical trials & a new Alzheimer's drug controversy
408: Whistleblower takes on health insurance and FDA commissioner candidates
Get summaries like this every morning.
Free AI-powered recaps of The Readout Loud and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.